The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Salazopyrin® 500 mg Tablets



Pfizer Healthcare IrelandPA0822/196/002

Main Information

Trade NameSalazopyrin® 500 mg Tablets
Active SubstancesSulfasalazine
Dosage FormTablet
Licence HolderPfizer Healthcare Ireland
Licence NumberPA0822/196/002

Group Information

ATC CodeA07EC Aminosalicylic acid and similar agents
A07EC01 sulfasalazine

Status

License statusAuthorised
Licence Issued01/04/1977
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back